Cellbion Co

Cellbion Co Equity

The The Equity of Cellbion Co (308430.KQ) as of Oct 16, 2026 is 22.79 B KRW. In the previous year, The Equity was 29.58 B KRW — a change of -22.95% (lower).

Equity

22.79 BKRW

YoY

-22.95%

Last updated:

In 2025, Cellbion Co's equity was 22.79 B KRW, a -22.95% increase from the 29.58 B KRW equity in the previous year.

The Cellbion Co Equity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity
Date
Equity
Jan 1, 2021
8.47 B KRW
Jan 1, 2022
2.74 B KRW
Jan 1, 2023
7.50 B KRW
Jan 1, 2024
29.58 B KRW
Jan 1, 2025
22.79 B KRW
The Cellbion Co Equity history
YEAREquityYoY
22.79 BKRW-22.95%
29.58 BKRW+294.47%
7.50 BKRW+173.79%
2.74 BKRW-67.68%
8.47 BKRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Cellbion Co Stock analysis

What does Cellbion Co do? Cellbion Co Ltd, headquartered in Seoul, South Korea, operates in the pharmaceutical and healthcare sector. The company develops innovative diagnostic and therapeutic drugs, engages in generic prescription drug manufacturing, and provides contract development and manufacturing services for clinical trial drugs. Additionally, Cellbion Co Ltd produces cosmetic products. Listed on October 16, 2024, the company employs 43 full-time staff. Cellbion Co is one of the most popular companies on Eulerpool.

Equity Details

Analyzing Cellbion Co's Equity

Cellbion Co's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Cellbion Co's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Cellbion Co's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Cellbion Co's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Cellbion Co’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Cellbion Co stock

The Equity of Cellbion Co is 22.79 B KRW in 2025.

The Equity of Cellbion Co changed from 29.58 B KRW to 22.79 B KRW, representing a -22.95% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of The Equity Cellbion Co since 2006 – with annual values, charts, and detailed analysis.

The Equity's KRW is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Equity's Cellbion Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Balance Sheet — Cellbion Co

Total AssetsCurrent AssetsCash & EquivalentsReceivablesInventoryProperty, Plant & EquipmentGoodwillIntangible AssetsEquityLiabilitiesDebtCurrent LiabilitiesLong-term DebtShort-term DebtRetained EarningsBook Value per ShareTangible Book Value per ShareWorking CapitalInvestmentsAccounts PayableNon-Current AssetsShort-Term InvestmentsLong-Term InvestmentsNet DebtTreasury StockMinority InterestDeferred Tax LiabilitiesNet Tangible AssetsGoodwill/AssetsIntangibles/Assets

All Key Metrics — Cellbion Co